Cingulate

Cingulate

Pharmaceutical Preparations

Company website
Foundation year

2013

About

Total Funding 

$7.6M


Cingulate Therapeutics uses a unique combination of delivery technology and proven medications that creates an unmatched release profile.

Their unique combination of cutting-edge delivery technology and proven medications will create an unmatched release profile - allowing for rapid onset of action, reliable duration lasting the entire active day, and a favorable tolerability profile - all within a once-daily, oral dose for superior patient efficacy, safety, and convenience.


Number of employees

10 - 20


Headquarters

Kansas City, KS, US

Underwriters

Werth Family Investment Associates


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.